Search This Blog

Tuesday, November 17, 2026

NRx wins first FDA drug approval, launches ketamine sales and targets profitability in 2027

 


  • NRx now estimates the ketamine market at about $400 million, down from $750 million cited on prior calls.
  • SPARC-TMS enrollment is delayed until 2027; $11.2M DARPA contract met initial milestones, with first Q4 invoices approved.
  • Fiscal Q3 2026 non-GAAP EPS of $-0.05 beat estimates, while $1.2M revenue missed, up from $0.2M in Q3 2025.
  • Net loss narrowed to $2.2M, or $0.05 per share, from $5.9M YoY.
  • FDA approved preservative-free IV ketamine in novel blow-fill-seal packaging on October 29.
  • Seventeen-person sales force launched; first commercial ketamine order arrived shortly after quarter-end.
  • Cash increased to $19.8M with no convertible debt remaining after equity raise.
  • Company reorganized into four divisions, each targeting non-dilutive funding and standalone profitability.
  • NRX-100 rolling NDA planned by year-end, with 2027 depression approval sought via regular or accelerated paths.
  • Hope Therapeutics runs six Florida clinics, expanding TMS capabilities and driving higher service revenue.
  • GeNeuro ALS and schizophrenia antibody programs viewed as major upside, with external funding targeted to limit dilution.
  • Main concern: Execution and regulatory risk across multiple programs while long-term funding still depends on external capital.
  • NRX-200 subcutaneous ketamine program announced alongside fiscal third-quarter results.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.